Investor's Business Daily on MSN
Travere, Ligand hammered on a surprise delay for their linchpin drug
Travere Therapeutics shares crashed Tuesday as investors digested a delay for its drug, Filspari, in treating a kidney ...
I am upgrading Travere Therapeutics, Inc. to a Buy, as the FDA's decision not to hold an AdCom suggests a favorable path for Filspari in FSGS. Filspari's strong sales growth, improved financials, and ...
Received 693 new patient start forms for FILSPARI ® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results